Michael Exton, CEO, highlighted, "Lexicon is advancing 3 very strong novel late-stage programs in the therapeutic areas of cardiometabolic disease and chronic pain." He emphasized progress in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results